Pinoxepin

Pinoxepin
Clinical data
Other namesPinoxepine; P-5227
Routes of
administration		Oral
Identifiers
IUPAC name
  • 2-[4-[(3Z)-3-(2-Chloro-6H-benzo[c][1]benzoxepin-11-ylidene)propyl]piperazin-1-yl]ethanol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC23H27ClN2O2
Molar mass398.93 g·mol−1
3D model (JSmol)
SMILES
  • C1CN(CCN1CC/C=C\2/C3=CC=CC=C3COC4=C2C=C(C=C4)Cl)CCO
InChI
  • InChI=1S/C23H27ClN2O2/c24-19-7-8-23-22(16-19)21(20-5-2-1-4-18(20)17-28-23)6-3-9-25-10-12-26(13-11-25)14-15-27/h1-2,4-8,16,27H,3,9-15,17H2/b21-6-
  • Key:RAAHIUIRJUOMAU-MPUCSWFWSA-N

Pinoxepin (INN; developmental code name P-5227; pinoxepin hydrochloride (USAN)) is an antipsychotic of the tricyclic group with a dibenzoxepin ring system which was developed in the 1960s but was never marketed.[1][2][3][4][5] It was found in clinical trials to have effectiveness in the treatment of schizophrenia similar to that of chlorpromazine and thioridazine.[4] The drug has marked sedative effects but causes relatively mild extrapyramidal symptoms.[2][4]

References

  1. ↑ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 984–. ISBN 978-1-4757-2085-3.
  2. 1 2 Annual Reports in Medicinal Chemistry. Academic Press. 1 January 1967. pp. 2–. ISBN 978-0-08-058346-4.
  3. ↑ Gordon M (2 December 2012). Psychopharmacological Agents. Elsevier Science. pp. 102–. ISBN 978-0-323-15128-3.
  4. 1 2 3 Iversen L (6 December 2012). Handbook of Psychopharmacology: Volume 10: Neoroleptics and Schizophrenia. Springer Science & Business Media. pp. 200–. ISBN 978-1-4613-4042-3.
  5. ↑ Lajtha A (11 November 2013). Alterations of Metabolites in the Nervous System. Springer Science & Business Media. pp. 335–. ISBN 978-1-4757-6740-7.



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.